Oppenheimer Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Oppenheimer Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$431K	Buy	1,364 +80	+6%	+$18.9K	﹤0.01%	917
2026 Q1	$256K	Buy	1,284 +101	+9%	+$20K	﹤0.01%	1002
2025 Q4	$224K	Buy	+1,183	New	+$227K	﹤0.01%	976
2021 Q1	–	Sell	-10,476	Closed	-$650K	–	1191
2020 Q4	$650K	Buy	10,476 +154	+1%	+$8.78K	0.01%	812
2020 Q3	$614K	Buy	10,322 +1,808	+21%	+$123K	0.01%	762
2020 Q2	$594K	Buy	8,514 +2,054	+32%	+$130K	0.01%	747
2020 Q1	$293K	Buy	+6,460	New	+$366K	0.01%	872
2019 Q3	–	Sell	-1,297	Closed	-$93K	–	1621
2019 Q2	$93K	Sell	1,297 -118	-8%	-$8.69K	﹤0.01%	1242
2019 Q1	$111K	Sell	1,415 -360	-20%	-$27.3K	﹤0.01%	1179
2018 Q4	$150K	Buy	+1,775	New	+$189K	﹤0.01%	1086
2017 Q4	–	Sell	-478	Closed	-$41K	–	1296
2017 Q3	$41K	Buy	+478	New	+$37.8K	﹤0.01%	1410

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer Asset Management's LGND Position: Q2 2026 in Review

Oppenheimer Asset Management increased its Ligand Pharmaceuticals (LGND) stake by 6.2% in Q2 2026, buying an estimated $18.9K and bringing the position to 1,364 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #917.

Oppenheimer Asset Management first reported a position in LGND in Q3 2017 and has held it in 11 quarters since. The position peaked at $650K in Q4 2020. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Oppenheimer Asset Management held 1,364 shares of Ligand Pharmaceuticals worth $431K as of Q2 2026.
Oppenheimer Asset Management bought 80 Ligand Pharmaceuticals shares in Q2 2026, an estimated $18.9K.
Ligand Pharmaceuticals made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #917 holding.
Oppenheimer Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2017 and has held it in 11 quarters since.
Oppenheimer Asset Management's Ligand Pharmaceuticals position peaked at $650K in Q4 2020.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.